Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Northwest Biotherapeutics (NWBO) over the last 16 years, with Q3 2025 value amounting to $70000.0.

  • Northwest Biotherapeutics' Amortizatization of Intangibles fell 909.09% to $70000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $277000.0, marking a year-over-year decrease of 1035.6%. This contributed to the annual value of $650000.0 for FY2020, which is 30186.34% up from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Amortizatization of Intangibles stood at $70000.0, which was down 909.09% from $66000.0 recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Amortizatization of Intangibles registered a high of $93000.0 during Q1 2021, and its lowest value of $56000.0 during Q2 2021.
  • Its 5-year average for Amortizatization of Intangibles is $70461.5, with a median of $70000.0 in 2025.
  • Within the past 5 years, the most significant YoY rise in Northwest Biotherapeutics' Amortizatization of Intangibles was 1625.0% (2021), while the steepest drop was 3372.09% (2021).
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Amortizatization of Intangibles stood at $57000.0 in 2021, then rose by 10.53% to $63000.0 in 2022, then rose by 15.87% to $73000.0 in 2023, then grew by 5.48% to $77000.0 in 2024, then dropped by 9.09% to $70000.0 in 2025.
  • Its last three reported values are $70000.0 in Q3 2025, $66000.0 for Q2 2025, and $64000.0 during Q1 2025.